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Abstract
Background: Epigenetic gene silencing is one of the major causes of carcinogenesis. Its widespread occurrence
in cancer genome could inactivate many cellular pathways including DNA repair, cell cycle control, apoptosis, cell
adherence, and detoxification. The abnormal promoter methylation might be a potential molecular marker for
cancer management.
Methods:  For rapid identification of potential targets for aberrant methylation in gynecological cancers,
methylation status of the CpG islands of 34 genes was determined using pooled DNA approach and methylation-
specific PCR. Pooled DNA mixture from each cancer type (50 cervical cancers, 50 endometrial cancers and 50
ovarian cancers) was made to form three test samples. The corresponding normal DNA from the patients of each
cancer type was also pooled to form the other three control samples. Methylated alleles detected in tumors, but
not in normal controls, were indicative of aberrant methylation in tumors. Having identified potential markers,
frequencies of methylation were further analyzed in individual samples. Markers identified are used to correlate
with clinico-pathological data of tumors using χ2 or Fisher's exact test.
Results: APC and p16 were hypermethylated across the three cancers. MINT31 and PTEN were hypermethylated
in cervical and ovarian cancers. Specific methylation was found in cervical cancer (including CDH1, DAPK, MGMT
and MINT2), endometrial cancer (CASP8, CDH13, hMLH1 and p73), and ovarian cancer (BRCA1, p14, p15, RIZ1
and TMS1). The frequencies of occurrence of hypermethylation in 4 candidate genes in individual samples of each
cancer type (DAPK, MGMT, p16 and PTEN in 127 cervical cancers; APC, CDH13, hMLH1 and p16 in 60 endometrial
cancers; and BRCA1, p14, p16 and PTEN in 49 ovarian cancers) were examined for further confirmation. Incidence
varied among different genes and in different cancer types ranging from the lowest 8.2% (PTEN in ovarian cancer)
to the highest 56.7% (DAPK in cervical cancer). Aberrant methylation for some genes (BRCA1, DAPK, hMLH1,
MGMT, p14, p16, and PTEN) was also associated with clinico-pathological data.
Conclusion: Thus, differential methylation profiles occur in the three types of gynecologic cancer. Detection of
methylation for critical loci is potentially useful as epigenetic markers in tumor classification. More studies using
a much larger sample size are needed to define the potential role of DNA methylation as marker for cancer
management.
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Background
Hypermethylation of the CpG islands of gene promoter is
one of the earliest and most frequent alterations leading
to cancer [1,2]. It is an important epigenetic mechanism
for gene silencing, which may confer tumor cells of
growth advantage [1,3]. Many cellular pathways are inac-
tivated by this epigenetic event, including DNA repair, cell
cycle, apoptosis, cell adherence, and detoxification [4].
Evidence showed that CpG island hypermethylation is
widespread in human genome. But it is not randomly dis-
tributed in carcinogenesis, and is gene-specific and cancer-
type specific [5-7]. The specific patterns of CpG island
hypermethylation between tumor types may provide a
useful signature for tumor diagnosis and prognosis [4,7-
9]. Moreover, genes that are frequently aberrantly methyl-
ated in specific tumors have been used as molecular tar-
gets for the detection of neoplastic cells in body fluids
such as urine and plasma which provide additional targets
for noninvasive early diagnosis and monitoring for can-
cers [9,10].
CpG island hypermethylation has been demonstrated in
gynecologic cancers [11-16]. However, studies were sepa-
rately performed in each of the three cancers. Since differ-
ent genes and different methods were employed, the
biological and clinical roles of this epigenetic event in
gynecologic cancers were not comparable among studies.
However, it is meaningful to compare the role for CpG
island hypermethylation in the development and progres-
sion of the three cancers because of the correlation in the
embryonic development of ovarian epithelium,
endometrium and cervix. Moreover, the numbers of CpG
islands investigated in those studies were very limited.
Recently, microarray-based techniques provide a powerful
tool to map methylation patterns in multiple genes and
multiple CpG sites within genes [17,18]. However, those
advanced techniques are not presently widely available.
For rapid identification of potential targets for aberrant
methylation in gynecological cancers as markers for can-
cer management, thus, in the present study with the tech-
nologies at hand, the pooled DNA approach and
methylation-specific PCR (MSP) were employed to deter-
mine the methylation status of 34 gene loci among the
three gynecologic cancers. Markers identified are used to
correlate with clinico-pathological data of tumors.
Methods
Patients
The study was approved by the Institutional Review
Board. Patients of 127 cases of cervical cancer, 60 cases of
endometrial cancer and 50 cases of ovarian cancer were
recruited for this study. Those patients were diagnosed
and treated in Queen Mary Hospital, Hong Kong from
January, 1990 to June, 2003. Primary tumor tissues and
paired normal tissues were obtained from biopsy or surgi-
cal specimens. The paired normal tissues taken from cer-
vical cancer patients are usually blood. From endometrial
cancer patients, the normal tissues are mainly cervix.
Patients with ovarian cancer, the normal tissues taken are
either from the cervix or the endometrium. Finally, the tis-
sues were maintained frozen in our tissue bank. Informed
consent was obtained from all individuals for the collec-
tion of tissue or blood.
The histological types and grades of tumor were classified
according to WHO criteria. The stage of each cancer was
established according to the International Federation of
Gynecology and Obstetrics (FIGO) criteria. Table 1 lists
the clinical characteristics and treatment modality for
those patients. All the patients were followed up after the
last treatment every 3 months for the first 2 years, every 6
months for the next 3 years, then yearly thereafter. The
end of the observation period was August, 2003. Response
to treatment was evaluated by physical examination,
appropriate imaging studies or biopsy. Persistent disease
was defined as detection of disease within 6 months after
completion of treatment. Recurrent disease was defined as
local (within pelvis) or distant (outside the pelvis) lesions
appearing after a disease-free interval of more than 6
months after completion of treatment.
DNA extraction and preparation of pooled DNA
Genomic DNA from tumor and paired normal tissues was
extracted using the standard Proteinase K treatment fol-
lowed by phenol/chloroform extraction. One μg of tumor
DNA from each of the 50 patients with same cancer type
(for cervical and endometrial cancer, these 50 patients
were randomly selected from the total 127 and 60
patients, respectively) was mixed together as the test DNA
pool (M2, M4 and M6 for cervical, endometrial and ovar-
ian cancers, respectively). Similarly, the paired normal
DNA from those patients was also pooled to form the con-
trols (M1, M3 and M5 for cervical, endometrial and ovar-
ian cancers, respectively).
DNA methylation analysis
CpG island methylation status for a total of 34 loci in the
three cancers was first assessed in the differential DNA
pools representing tumor and normal DNA by MSP. The
methylation status of each locus has already been
reported in one or multiple cancer types (see Additional
file 1). A pair of primers for each locus, which only recog-
nizes methylated sequence, was used to amplify the
sequence of interest. Methylated alleles detected in tumor
DNA pool, but not in normal DNA pool, were indicative
of aberrant methylation in tumors. Furthermore, nine
loci, which were aberrantly methylated in tumors sugges-
tive by the above analysis, were selected for subsequent
methylation analysis in individual samples including 127BMC Cancer 2006, 6:212 http://www.biomedcentral.com/1471-2407/6/212
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cervical cancers, 60 endometrial cancers and 49 ovarian
cancers (DNA was not sufficient in one case). Another set
of primer pair for each locus, which only recognizes
unmethylated alleles, was added to discriminate the
methylated and unmethylated sequences for each sample.
A placenta DNA sample treated in vitro with SssI methyl-
transferase (New England Biolabs Inc., Beverly, MA) fol-
lowed by bisulfite treatment was used as a positive control
for methylated allele and as a negative control for the
unmethylated allele. A placenta DNA without pre-treat-
ment of SssI methyltransferase prior modification, and a
placenta DNA without any treatment were used as nega-
tive controls for the methylated allele.
Sodium-bisulfite treatment, MSP and sequencing
The bisulfite treatment of DNA, MSP conditions and
sequencing of PCR products have been described in our
previous report [16]. Primer sequences and annealing
temperature were same as those published reports. Details
of the primers, annealing temperature, product size are
listed [see Additional file 1].
Data analysis and statistics
The association between aberrant hypermethylation and
clinico-pathological parameters was tested by the χ2 test
or Fisher's exact test. The t-test was used to compare the
mean age of different groups. All variables (age, stage,
grade, histological type, and CpG island hypermethyla-
tion) were also subjected to multivariate analysis using
Logistic regression. Disease-free survival (DFS) was
defined as the period from the completion of the last
treatment to the date of the first documented evidence of
recurrent disease. Patients without recurrent disease were
censored at their last follow-up visit or death. Overall sur-
vival (OS) was calculated from the date of diagnosis to
death; patients who survived until the end of the observa-
tion period were censored at their last follow-up visit.
Patients who died because of other causes than cancer
were censored at their date of death. Survival analysis was
performed by the method of Kaplan-Meier, and differ-
ences between groups were determined by log-rank test.
The Cox proportional hazards model was used for multi-
variate survival analysis. CpG island hypermethylation,
Table 1: Clinical characteristics of all patients with gynecologic cancers.
Cervical cancer Endometrial cancer Ovarian cancer
Cases 127 60 50
Mean age (years) 51.9 (22–101) 58.2 (23–81) 48.8 (26–79)
FIGO stage
I6 1 4 6 1 5
II 46 6 9
III 17 6 20
IV 3 2 6
Grade
G1 40 35 6
G2 53 17 16
G3 31 8 26
Unclear 3 2
Histological type
Squamous 98
Adenocarcinoma 29
Serous 17
Mucinous 10
Endometrioid 60 11
Clear cell 6
Others 6
Treatment
ST 32 38 6
RT 44
CT
ST+RT 19 21
ST+CT 41
RT+CT+/- ST 30 1 3a
No treatment 2
ST: surgery; RT: radiotherapy; CT: chemotherapy
aThose three patients have double primary cancers.BMC Cancer 2006, 6:212 http://www.biomedcentral.com/1471-2407/6/212
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patients' age, FIGO stage, tumor grading and histological
type were included in the regression model. All the statis-
tical analysis was performed using the software SPSS for
Windows version 13.0. P < 0.05 was taken as statistically
significant.
Results
Identification of CpG island methylation profiles in 
gynecologic cancers
Figure 1 shows the methylated alleles for some gene loci
produced by MSP in the tumor and normal DNA pools of
the three cancers. The methylation status for the 34 loci in
the three cancers was summarized in Figure 2. Among
those 34 loci, (1) aberrant methylation of APC and p16
was detected across the three cancers; (2) MINT31 and
PTEN were aberrantly methylated in both cervical cancer
and ovarian cancer; (3) specifically, aberrant methylation
for CDH1, DAPK, MGMT and MINT2 was only present in
cervical cancer; CASP8, CDH13, hMLH1 and p73 were just
methylated in endometrial cancer; aberrant methylation
for BRCA1, p14, p15, RIZ and TMS1 was only detected in
ovarian cancer. For the other loci, aberrant methylation
was not indicated in any of the three cancers because
methylated alleles were present in both tumor and nor-
mal DNA (i.e. methylation occurred in that particular
gene in both tumor and normal tissues) e.g. FHIT gene
(Figure 2), or methylated allele was not detected in both
(i.e. methylation did not occur in that particular gene in
both tumor and normal tissues) e.g. ALX3 gene (Figure 2).
Confirmation of hypermethylation for candidate genes in 
primary tumors
For further confirmation, 9 loci with aberrant methylation
in the three cancers were further studied by MSP in indi-
vidual primary tumors. The incidence of methylation for
these loci in the three cancers and their association with
clinico-pathological parameters and prognosis were also
determined. Four loci including DAPK, MGMT, p16 and
PTEN were selected for methylation analysis in 127 cervi-
cal cancers; APC, CDH13, p16 and hMLH1 were examined
in 60 endometrial cancers; and BRCA1,  p14,  p16  and
PTEN in 49 ovarian cancers. Figure 3 shows the methyl-
ated and unmethylated alleles produced by MSP in repre-
sentative samples. Methylation for at least one gene was
detectable in 72.4% (92/127) of cervical cancers (Table
2), 66.7% (40/60) of endometrial cancers (Table 3) and
51.0% (25/49) of ovarian cancers (Table 4). Incidence of
hypermethylation for DAPK, MGMT, p16 and PTEN in
cervical cancer was 56.7%, 25.2%, 16.5% and 15.7%
respectively. Incidence for APC, CDH13, p16 and hMLH1
in endometrial cancer was 41.7%, 35.0%, 25.0% and
13.3% respectively. Incidence for BRCA1, p14, p16 and
PTEN in ovarian cancer was 24.5%, 18.4%, 16.3% and
8.2% respectively. Although we found genes specific for
each type of the three tumors, we deliberately chose p16
and PTEN to determine if the frequencies of methylation
are different between different tumors. From the above
results, no obvious difference was observed in the methyl-
ation frequencies of p16  and  PTEN  in the different
tumors.
Identification of CpG island hypermethylation by pooled DNA approach and MSP Figure 1
Identification of CpG island hypermethylation by pooled DNA approach and MSP. Methylated alleles for some 
gene loci produced by MSP in tumor and normal DNA pools of the three types of gynecologic cancer. M: 50 bp DNA marker; 
M1 and M2: normal DNA and tumor DNA pools of cervical cancer; M3 and M4: normal DNA and tumor DNA pools of 
endometrial cancer; M5 and M6: normal DNA and tumor DNA pools of ovarian cancer; M7: a sodium bisulfite-treated placenta 
DNA, but without pre-treatment of SssI methyltransferase; M8: an un-treated placenta DNA; M9: a placenta DNA treated with 
SssI methyltransferase followed by sodium-bisulfite. The arrows indicate the positions of the PCR products.
MM 1 M 2 M 3 M 4 M 5 M 6 M 7 M8 M9 M M 1M 2 M 3M 4M 5M 6M 7M8 M9 MM 1 M 2 M 3 M 4 M 5M 6M 7M8 M9
APC DAPK BRCA1
p16 hMLH1 FHIT
PTEN TMS1 MGMTBMC Cancer 2006, 6:212 http://www.biomedcentral.com/1471-2407/6/212
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CpG island hypermethylation in relation to clinico-
pathological parameters
Tables 2, 3 &4 show the association between CpG island
hypermethylation of the nine loci and the clinico-patho-
logical parameters in the three cancers. Hypermethylation
for some specific loci was related to particular tumor sub-
types. In cervical cancer (Table 2), DAPK gene hypermeth-
ylation was more frequently detected in squamous cell
carcinoma (SCC) than in adenocarcinoma (AC) (63.3%
versus 34.5%, P = 0.006), whereas, PTEN was more fre-
quently detected in AC than in SCC (34.5% versus 10.2%,
P = 0.002). The two findings were confirmed by multivar-
iate analysis (P = 0.004, and 0.002, respectively). A signif-
icant correlation was observed between MGMT
hypermethylation and the early-stage tumor (P = 0.03),
but was not confirmed by multivariate analysis (P  =
0.733).
In endometrial cancer (Table 3), hMLH1 gene hypermeth-
ylation was more common in moderately or poorly differ-
entiated tumors (G2 & G3) than in well-differentiated
tumors (G1) (28% versus 2.8%, P = 0.007), which was
confirmed by multivariate analysis (P = 0.032). p16 gene
hypermethylation only existed in 15 (32.6%) of 46 stage
I carcinomas and none of the 14 stages II-IV carcinomas
was positive (P = 0.014). But, the association between p16
gene hypermethylation and early-stage tumor was not
confirmed by multivariate analysis (P = 0.748).
In ovarian cancer (Table 4), hypermethylation of BRCA1
was detected at a significantly higher frequency in serous
carcinomas than in tumors of the other histological types
(35.3% versus 6.2%, P  = 0.015], whereas, PTEN  were
more frequently detected in mucinous carcinoma than in
tumors of the other histological types (30% versus 2.6%,
P = 0.023). Hypermethylation of p16 gene was detected in
33.3% (9/27) of serous or mucinous carcinomas, but not
in any of the tumors of other histological types (P  <
0.001). Additionally, p14 hypermethylation was associ-
ated with low-grade tumor (40.9% in G1 + G2 versus
12.0% in G3, P = 0.023) and early-stage cancer (37.5% in
stage I+II versus 12.0% in stage III+IV, P = 0.038). Hyper-
methylation of PTEN was also associated with low-grade
tumor, whereas, BRCA1 was associated with high-grade
tumor (P = 0.026, 0.033 respectively). However, only the
association between BRCA1 gene hypermethylation and
serous carcinoma was confirmed by multivariate analysis
(P = 0.045). More cases are needed for the confirmation
of the other findings.
Methylation-based prediction for therapeutic outcome 
and prognosis
Among 127 cervical cancer patients, there were a total of
31 deaths and 8 patients defaulted follow-up at 3 to 22
months with a median of 11.6 months. The remaining 88
patients had no evidence of disease on last follow-up at 3
to 153 months with a median of 83.7 months.
Table 2: Association of CpG island hypermethylation and clinico-pathological parameters in cervical cancer.
All subjects DAPK p16 MGMT PTEN Any loci
+-+-+-+-+-
Cases 127 72 55 32 95 21 106 20 107 92 35
Mean age (yrs) 51.9 52.8 50.7 53.5 51.4 49.8 52.3 52.9 51.7 53.0 48.9
P value(t-test) 0.422 0.484 0.463 0.734 0.152
Stage
I 6 13 1 3 01 9 4 21 4 4 71 1 5 04 1 2 0
II 46 27 19 11 35 7 39 7 39 36 10
III-IV 20 14 6 2 18 0 20 2 18 15 5
P value(χ2 test) 0.305 0.162 0.030c 0.688 0.431
Gradea
G1 40 25 15 13 27 7 33 8 32 31 9
G2–3 84 46 38 18 66 13 71 12 72 60 24
P value(χ2 test) 0.416 0.183 0.775 0.419 0.475
Histological type
S C C 9 86 2 3 62 4 7 41 6 8 21 0 8 87 4 2 4
AC 29 10 19 8 21 5 24 10 19 18 11
P value(χ2 test) 0.006 0.736 0.907 0.002 0.155
Response to radiotherapyb
Radiosensitive 44 30 14 12 32 8 36 5 39 36 8
Radioresistant 19 9 10 3 16 2 17 3 16 11 8
P value(χ2 test) 0.118 0.326 0.445 0.628 0.045
aWHO grading is not available for three cases.
bA total of 63 cases received primary radiotherapy and had the data of response to radiotherapy. cComparison was made between stages I+II and 
stages III+IV.BMC Cancer 2006, 6:212 http://www.biomedcentral.com/1471-2407/6/212
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In survival analysis, the mean of overall survival (OS) was
114.3 months (95% confidence interval: 102.8–125.8
months). Using univariate survival analysis, FIGO stage
was significantly associated with OS with estimated 5 year
survival of 89% for stage I, 72% for stage II and 40% for
stage III and IV (log rank test, P < 0.001). Modalities of
treatment also was significantly associated with OS with
estimated 5 year survival of 93% for patients treated by
radical surgery, 86% for patients treated by radical surgery
and radiotherapy and 66% for those treated by radiother-
apy with or without chemotherapy (log-rank test, P  =
0.022). Women younger than 51 had better survival than
older women (5 year survival rate 83 vs 67%, log-rank test
P = 0.015).
No significant association of survival was found in rela-
tion to grade 1 vs grades 2 & 3 (P = 0.066), histology types,
methylation status of DAPK  (P  = 0.16), MGMT  (P  =
0.504), p16 (P = 0.258) and PTEN (P = 0.541). On multi-
variate analysis using Cox forward logistic regression with
age, grade, stage, histology types, methylation status of
DAPK, MGMT, p16 and PTEN, treatment modalities, only
stage (P = 0.003, odds ratio = 1.9) remained as independ-
ent significant factor.
To evaluate the role of CpG island hypermethylation in
the prediction of response to radiotherapy, 63 cervical
cancer patients underwent primary radiotherapy were
analyzed. Tumors were divided into radiosensitive and
radioresistant groups based on the histological findings of
residual tumor cells in the cervical biopsy specimens
taken after the completion of external radiotherapy and
brachytherapy. If there are no residual viable tumor cells
in cervical biopsies, the tumor is defined as radiosensitive.
Forty-four tumors were radiosensitive and 19 tumors were
radioresistant. Tumors with methylation for any of the
four genes were more sensitive to radiotherapy than
tumors without (76.6% vs 50.0%, P = 0.045) (Table 2).
In endometrial cancer and ovarian cancer, no significant
association was found between CpG island hypermethyl-
ation and overall survival. Using univariate survival anal-
ysis, none of the methylation status reached P < 0.05 (log-
rank test). Larger sample size is needed for further confir-
mation.
Discussion
Rapid DNA methylation analysis by pooled DNA approach 
and MSP
Previous methods for DNA methylation analysis, such as
Southern-blot analysis, bisulfite genomic DNA sequenc-
ing, and restriction enzyme digestion, require large
amounts of DNA. The number of CpG islands investi-
gated and sample sizes are also limited. Recently, some
high-throughput approaches are developed for the large-
Methylation status of the 34 gene loci in the three types of  gynecologic cancer Figure 2
Methylation status of the 34 gene loci in the three 
types of gynecologic cancer. (■) Presence of methylated 
alleles. () Absence of methylated alleles.
APC
P16
MINT31
PTEN
RAR-ȕ2
BRCA1
p14
p15
RIZ1
TMS1
CASP8
CDH13
hMLH1
p73
CDH1
DAPK
HIC
MGMT
MINT1
MINT2
RASSF1A
ALX3
AR
BRCA2
CACNA1G
FHIT
hMSH2
HMSH3
MINT32
RB
STK11
THBS1
TIMP
VHL
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scale analysis of multiple CpG islands including restric-
tion landmark genomic scanning, differential methyla-
tion hybridization [17], and methylation specific
oligonucleotide microarray [18]. However, there are some
practical problems with these methods in dealing with
clinical specimens. The discriminative ability of each
probe is hampered by its different hybridization efficiency
between methylated and unmethylated alleles. Moreover,
these techniques need the most advanced chip technology
and informatics approaches, which might not be widely
available.
Compared to bisulfite sequencing, MSP is much simpler,
requires less time and avoids the use of expensive
sequencing reagents. Furthermore, simultaneous detec-
tion of unmethylated and methylated products in a single
sample by MSP confirms the integrity of DNA as a tem-
plate for PCR and allows a semi-quantitative assessment
of allele types. Thus, in the present study, the pooled DNA
approach and MSP were employed to screen those loci
with aberrant methylation in tumors by comparing the
methylation status in pooled tumor DNA and normal
DNA. Only those loci with aberrant methylation in tumor
were recognized as the potential epigenetic markers.
Those loci with the same methylation status (presence or
absence of methylated allele) in tumor and normal DNA
pools were excluded for further study. In the present
study, DNA methylation profiles in the three gynecologic
cancers were compared easily and rapidly using the
method introduced here.
Differential DNA methylation profiles exist in gynecologic 
cancers
Specific pattern of CpG island hypermethylation existing
in each human cancer was first reported by Costello et al.
[5], and confirmed by Esteller et al. [6]. In the present
study, 34 loci were randomly chosen for investigation.
Those genes involve in many cellular pathways and have
critical biological functions. Multiple genes were aber-
rantly methylated in the three cancers; in which some
genes have been confirmed in other laboratories studying
a single tumor type, whereas, others have not been
reported before [15,16] and [19-25]. For each cancer type,
aberrant methylation for several pathways happened
Methylated (M) and unmethylated (U) alleles for six genes  produced by MSP in representative samples Figure 3
Methylated (M) and unmethylated (U) alleles for six 
genes produced by MSP in representative samples. 
(A) APC: methylated alleles were detected in cases A1, A5, 
A7 and A8; (B) BRCA1: methylated alleles were detected in 
cases B1, B2, B4, B5, B6 and B7; (C) DAPK: methylated alle-
les were detected in cases C1, C2, C5, C6, C7 and C8; (D) 
hMLH1: methylated alleles were detected in case D1, D3 and 
D6; (E) p16: methylated alleles were detected in cases E2 
and E5; (F) PTEN: methylated alleles were detected in cases 
F1, F3, F4 and F6.
UM
1
UM
2
UM
3
UM
4
UM
5
UM
6
UM
7
UM
8
A
B
C
D
E
F
Table 3: Association of CpG island hypermethylation and clinico-pathological parameters in endometrial cancer.
All subjects CDH13 APC p16 hMLH1 Any loci
+-+-+-+-+-
Case 60 25 35 21 39 15 45 8 52 40 20
Mean age (yrs) 58.2 59.2 57.5 58.4 58.1 59.3 57.9 62.2 57.6 59.3 56.0
P value (T-test) 0.619 0.944 0.724 0.377 0.38
Stage
I 4 62 0 2 61 7 2 91 5 3 1 6 4 03 5 1 1
I I - I V 1 45 941 001 421 25 9
P value(χ2 test) 0.606 0.565 0.014 0.905 0.005
Grade
G1 35 12 23 10 25 11 24 1 34 22 13
G2–3 25 13 12 11 14 4 21 7 18 18 7
P value(χ2 test) 0.17 0.217 0.174 0.007 0.459BMC Cancer 2006, 6:212 http://www.biomedcentral.com/1471-2407/6/212
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simultaneously. For example, genes involved in cell cycle
(p16), apoptosis (DAPK), cell adherence (CDH1), DNA
repair (MGMT), and APC/β-cateninroute (APC) were
found to be aberrantly methylated in cervical cancer.
However, the profile of CpG island hypermethylation for
the 34 loci differed among the three types of gynecologic
cancers (Figure 2).
Hypermethylation of the p16 gene has been suggested to
be a shared epigenetic alteration in multiple human can-
cers [6]. It was also observed across the three gynecologic
cancers in the present study. The association between
DAPK hypermethylation and SCC has been reported in
our previous study [16] other studies [20,24]. In this
study, aberrant methylation for the DAPK gene was only
observed in cervical cancer, of which 80% of the samples
were SCC. It was not detected in endometrial and ovarian
cancers, both of which are AC. Thus, DAPK gene is selec-
tively methylated in the development of SCC. hMLH1 is
one of the DNA mismatch repair genes. Inactivation of
hMLH1  results in microsatellite instability (MSI) in
tumors [25]. MSI is predominant in tumors associated
with HNPCC including endometrial cancer. Our previous
study has found that a higher frequency of MSI was
detected in endometrial cancer than in ovarian and cervi-
cal cancers (unpublished data), which could explain the
presence of aberrant methylation of hMLH1  gene in
endometrial cancer, but absence in cervical cancer and
ovarian cancer. Thus, hMLH1 is susceptible to methyla-
tion in the development of endometrial cancer. BRCA1 is
critical in the development of breast and ovarian cancers.
Germline mutations account for most of the cases with
hereditary breast and/or ovarian cancers [26]. However, in
sporadic cancer, promoter hypermethylation, not somatic
mutation, is the cause for BRCA1 inactivation [27]. In the
present study, BRCA1 was specifically methylated in ovar-
ian cancer, but not in the other two cancers. These obser-
vations have been confirmed in other laboratories
studying a single tumor type. Thus, our results consist-
ently demonstrate that differential DNA methylation pro-
files exist in the three gynecologic cancers.
Finally, we would like to raise a query concerning the
FHIT gene. Our own result indicates that methylated alle-
les were found in all tumor and normal DNA (Figure 1)
i.e. FHIT methylation was not tumor-specific. In contrast,
it has been demonstrated that aberrant methylation of
FHIT occurred specifically in lung and breast cancers [28].
However, in a study of FHIT methylation in cervical can-
cer, the methylation pattern identified by bisulfite
genomic sequencing did not correlate with the MSP [29].
The authors suggested that false-positive results might be
resulted from mispriming in the MSP assay. In this study,
we used the primers exactly the same as those published
information. Thus, one should be cautious when using
biomarker for cancer. The recent publications on frequen-
Table 4: Association of CpG island hypermethylation and clinico-pathological parameters in ovarian cancer.
All Subjects p14 BRCA1 PTEN p16 Any loci
+-+-+ - + - + -
Cases 49 12 37 8 41 4 45 9 40 25 24
Mean age (yrs) 48.8 47.6 49.2 44.0 49.8 65.1 47.4 52.6 48.0 47.8 49.9
P value (T-test) 0.7 0.239 0.006 0.321 0.559
Stage
I-II 24 9 15 2 22 2 22 4 20 12 12
III-IV 25 3 22 6 19 2 23 5 20 13 12
P value (χ2 test) 0.038 0.138 0.966 0.763 0.889
Gradea
G1–2 22 9 13 1 21 4 18 6 16 13 9
G3 25 3 22 7 18 0 25 3 22 12 13
P value (χ2 test) 0.023 0.033 0.026 0.184 0.447
Histological type 49
Serous 17 2 15 6 11 1 16 3 14 11 6
M u c i n o u s 1 03 71 93 76 47 3
Endometrioid 10 3 7 1 9 0 10 0 10 3 7
C l e a r - c e l l 6 3 3 06 06 0 6 33
O t h e r s 61 50 60 60 61 5
P value (χ2 test] 0.08b 0.015c 0.023d <0.001e 0.015e
aWho grading was not available for 2 cases.
bComparison was made between mucinous/endometrioid/clear-cell and the other types.
cComparison was made between serous and the other types.
dComparison was made between mucinous and the other types.
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cies of FHIT methylation in human cancer have been tab-
ulated [see Additional file 2] as references for those
readers particularly interested in studying FHIT.
Clinical implications of CpG island hypermethylation in 
gynecologic cancers
Esteller et al. [6] analyzed a series of promoter CpG island
hypermethylation changes for 12 genes in DNA from over
600 primary tumor samples representing 15 major tumor
types and concluded that a panel of three to four markers
could define an abnormality in 70–90% of each cancer
type. Thus, in the present study, 4 markers were chosen
from all genes with aberrant methylation in each of the
three cancers to determine the incidence of methylation in
that particular cancer type and to define their role in can-
cer diagnosis and prognosis. Hypermethylation in any of
the four genes investigated in each cancer type was
detected in 50–70% of the patients. In each cancer type,
methylation frequency varied among the four genes inves-
tigated, which indicated that CpG islands might differ in
their susceptibility to de novo methylation.
Furthermore, association analysis demonstrated that
hypermethylation of particular CpG islands was corre-
lated with clinico-pathological parameters (tumor histol-
ogy, grade or stage) and treatment response, which
produced distinct epigenetic signatures for particular
tumor subtypes. Thus, this epigenetic event has the poten-
tial to be used as a molecular marker for cancer diagnosis
and prognosis in gynecologic cancers. The most signifi-
cant finding is the DAPK gene hypermethylation in cervi-
cal cancer. DAPK, a pro-apoptotic serine/threonine
kinase, involves in apoptosis and plays a role in tumor
pathogenesis and metastasis when inactivated [30,31].
Inactivation of DAPK, mainly by promoter hypermethyla-
tion, has been demonstrated in some tumor types and
found to be associated with aggressive and metastatic phe-
notype [32-35]. In cervical cancer, the correlation between
DAPK gene hypermethylation and SCC demonstrated by
other studies was further confirmed in this study. Our in-
vitro study has shown that methylated promoter of DAPK
was present in the radio-resistant cervical cancer cell line,
SiHa; while absent in the radio-sensitive cell line, C4–1
(unpublished data). Moreover, the expression of DAPK
was down regulated in SiHa cell line, but reactivated by
exposure to the demethylation reagent (5-Aza-2' deoxycy-
tidine), which was consistent to the findings by Narayan
et al. [24]. Furthermore, our recent study has found that
DAPK  gene hypermethylation was detected in 50% of
plasma samples of cervical cancer patients [16]. Thus,
DAPK gene hypermethylation might be a valuable marker
for tumor diagnosis, and evaluation of treatment outcome
in cervical cancer. Because of its high frequency of meth-
ylation in cervical cancer, it might also be potentially used
as a therapeutic target for cervical cancer treatment.
Conclusion
Pooled DNA combined with MSP provides a useful
approach for rapid methylation analysis of a large number
of genes in multiple cancer types. CpG island hypermeth-
ylation is a frequent event in the development of the three
gynecologic cancers. Differential methylation profiles
exist in the three cancers and their subtypes. More studies
using a much larger sample size are needed to further
define the potential role of methylated DNA marker in
cancer management.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
HJY performed most of the MSP analysis and prepared the
draft of the manuscript. YW and PCKT did the DNA
extraction and the initial MSP conditions testing. VWSL
performed some of the MSP analysis, literature search and
the preparing of the final manuscript. HYSN involved in
the collection of samples and the analysis of the correla-
tion between experimental and clinical data.
Additional material
Acknowledgements
This work was supported by University of Hong Kong Conference and 
Research Grant (10205921).
References
1. Baylin SB, Herman JG: DNA hypermethylation in tumorigene-
sis: epigenetics joins genetics.  Trends Genet 2000, 16:168-174.
2. Jones PA, Baylin SB: The fundamental role of epigenetic events
in cancer.  Nat Rev Genet 2002, 3:415-428.
3. Jones PA, Laird PW: Cancer epigenetics comes of age.  Nat Genet
1999, 21:163-167.
4. Esteller M: CpG island hypermethylation and tumor suppres-
sor genes: a booming present, a brighter future.  Oncogene
2002, 21:5427-5440.
Additional File 1
Primer sequence, genomic position, MSP condition and product size. The 
file contains the information on the primer sequences, genomic positions, 
MSP conditions and product sizes of the 34 loci analyzed in the present 
study.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-6-212-S1.doc]
Additional File 2
Frequencies of FHIT gene methylation in various normal and tumor tis-
sues of human cancers. The file contains the information on the frequen-
cies of the FHIT gene methylation in various normal and tumor tissues of 
human cancers published in the last few years.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-6-212-S2.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2006, 6:212 http://www.biomedcentral.com/1471-2407/6/212
Page 10 of 10
(page number not for citation purposes)
5. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao
X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L,
Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su HH, Petrelli
NJ, Zhang X, O'dorisio MS, Held WA, Cavenee WK, Plass C: Aber-
rant CpG-island methylation has non-random and tumour-
type-specific patterns.  Nat Genet 2000, 24:132-138.
6. Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethyl-
ation profile of human cancer.  Cancer Res 2001, 61:3225-3229.
7. Patel A, Groopman JD, Umar A: DNA methylation as a cancer-
specific biomarker: from molecules to populations.  Ann N Y
Acad Sci 2003, 983:286-297.
8. Esteller M: Relevance of DNA methylation in the manage-
ment of cancer.  Lancet Oncol 2003, 4:351-358.
9. Laird PW: The power and the promise of DNA methylation
markers.  Nat Rev Cancer 2003, 3:253-266.
10. Cottrell SE, Laird PW: Sensitive detection of DNA methylation.
Ann N Y Acad Sci 2003, 983:120-130.
11. Catteau A, Harris WH, Xu CF, Solomon E: Methylation of the
BRCA1 promoter region in sporadic breast and ovarian can-
cer: correlation with disease characteristics.  Oncogene 1999,
18:1957-1965.
12. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, Karlan
BY: BRCA1 promoter region hypermethylation in ovarian
carcinoma: a population-based study.  Cancer Res 2000,
60:5329-5333.
13. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E,
Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M,
Baylin SB, Herman JG: Promoter hypermethylation and BRCA1
inactivation in sporadic breast and ovarian tumors.  J Natl Can-
cer Inst 2000, 92:564-569.
14. Salvesen HB, Macdonald N, Ryan A, Jacobs IJ, Lynch ED, Akslen LA,
Das S: PTEN methylation is associated with advanced stage
and microsatellite instability in endometrial carcinoma.  Int J
Cancer 2001, 91:22-26.
15. Zysman M, Saka A, Millar A, Knight J, Chapman W, Bapat B: Methyl-
ation of adenomatous polyposis coli in endometrial cancer
occurs more frequently in tumors with microsatellite insta-
bility phenotype.  Cancer Res 2002, 62:3663-3666.
16. Yang HJ, Liu VWS, Wang Y, Chan KYK, Tsang PCK, Khoo US, Cheung
ANY, Ngan HYS: Detection of Hypermethylated Genes in
Tumour and Plasma of Cervical Cancer Patients.  Gynecol
Oncol 2004, 93:435-440.
17. Ahluwalia A, Yan P, Hurteau JA, Bigsby RM, Jung SH, Huang TH,
Nephew KP: DNA Methylation and Ovarian Cancer: Analysis
of CpG Island Hypermethylation in Human Ovarian Cancer
Using Differential Methylation Hybridization.  Gynecologic
Oncology 2001, 82:261-268.
18. Shi H, Maier S, Nimmrich I, Yan PS, Caldwell CW, Olek A, Huang TH:
Oligonucleotide-based microarray for DNA methylation
analysis: principles and applications.  J Cell Biochem 2003,
88:138-143.
19. Salvesen HB, Macdonald N, Ryan A, Iversen OE, Jacobs IJ, Akslen LA,
Das S: Methylation of hMLH1 in a population-based series of
endometrial carcinomas.  Clin Cancer Res 2000, 6:3607-3613.
20. Dong SM, Kim HS, Rha SH, Sidransky D: Promoter hypermethyl-
ation of multiple genes in carcinoma of the uterine cervix.
Clin Cancer Res 2001, 7:1982-1986.
21. Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, Paul J, Brown
R: Primary ovarian carcinomas display multiple methylator
phenotypes involving known tumor suppressor genes.  Am J
Pathol 2001, 158:1121-1127.
22. Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, Minna JD,
Mok SC, Girard L, Fishman DA, Gazdar AF: Methylation profiles
of sporadic ovarian tumors and nonmalignant ovaries from
high-risk women.  Clin Cancer Res 2002, 8:3324-3331.
23. Horowitz N, Pinto K, Mutch DG, Herzog TJ, Rader JS, Gibb R,
Bocker-Edmonston T, Goodfellow PJ: Microsatellite instability,
MLH1 promoter methylation, loss of mismatch repair in
endometrial cancer and concomitant atypical hyperplasia.
Gynecol Oncol 2002, 86:62-68.
24. Narayan G, Arias-pulido H, Koul S, Vargas H, Zhang FF, Villella J, Sch-
neider A, Terry MB, Mansukhani M, Murty VV: Frequent Promoter
Methylation of CDH1, DAPK, RARB, and HIC1 Genes in
Carcinoma of Cervix Uteri: Its Relationship to Clinical Out-
come.  Mol Cancer 2003, 2:24.
25. Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG: MLH1 pro-
moter hypermethylation is associated with the microsatel-
lite instability phenotype in sporadic endometrial
carcinomas.  Oncogene 1998, 17:2413-2417.
26. Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA,
Ponder BA, Weber BL, Garber JE, Birch JM, Cornelis RS, Kelsell DP,
Spurr NK, Smyth E, Haites N, Sobol H, Bignon YJ, Chang-Claude J,
Hamann U, Lindblom A, Borg A, Piver SM, Gallion HH, Struewing JP,
Whittemore PT, Goldgar DE, Easton DF: An evaluation of genetic
heterogeneity in 145 breast-ovarian cancer families. Breast
Cancer Linkage Consortium.  Am J Hum Genet 1995, 56:254-264.
27. McCoy ML, Mueller CR, Roskelley CD: The role of the breast
cancer susceptibility gene BRCA1 in sporadic epithelial ovar-
ian cancer.  Reprod Biol Endocrinol 2003, 1:72.
28. Zöchbauer-Müller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R,
Virmani AK, Milchgrub S, Gazdar AF, Minna JD: 5' CpG Island
Methylation of the FHIT Gene Is Correlated with Loss of
Gene Expression in Lung and Breast Cancer.  Cancer Res 2001,
61:3581-3585.
29. Lea JS, Ashfaq R, Muneer S, Burbee DG, Miller DS, Minna JD, Muller
CY: Understanding the mechanisms of FHIT inactivation in
cervical cancer for biomarker development.  J Soc Gynecol Inves-
tig 2004, 11:329-337.
30. Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A: Identification
of a novel serine/threonine kinase and a novel 15-kD protein
as potential mediators of the gamma interferon-induced cell
death.  Genes Dev 1995, 9:15-30.
31. Inbal B, Cohen O, Polak-Charcon S, Kopolovic J, Vadai E, Eisenbach
L, Kimchi A: DAP kinase links the control of apoptosis to
metastasis.  Nature 1997, 390:180-184.
32. Katzenellenbogen RA, Baylin SB, Herman JG: Hypermethylation of
the DAP-kinase CpG island is a common alteration in B-cell
malignancies.  Blood 1999, 93:4347-4353.
33. Kwong J, Lo KW, To KF, Teo PM, Johnson PJ, Huang DP: Promoter
hypermethylation of multiple genes in nasopharyngeal carci-
noma.  Clin Cancer Res 2002, 8:131-137.
34. Simpson DJ, Clayton RN, Farrell WE: Preferential loss of Death
Associated Protein kinase expression in invasive pituitary
tumours is associated with either CpG island methylation or
homozygous deletion.  Oncogene 2002, 21:1217-1224.
35. Toyooka S, Toyooka KO, Miyajima K, Reddy JL, Toyota M, Sathy-
anarayana UG, Padar A, Tockman MS, Lam S, Shivapurkar N, Gazdar
AF: Epigenetic Down-Regulation of Death-associated Protein
Kinase in Lung Cancers.  Clin Cancer Res 2003, 9:3034-3041.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/6/212/pre
pub